Stock market recommendations: Emcure Pharmaceuticals, and Cholamandalam Investment & Finance Company Ltd – Motilal Oswal Wealth Management Research Desk has identified these as the top stocks to buy in the holiday-shortened trading week starting September 18, 2026:
| NAME | CMP (Rs) | TP (Rs) | Upside (%) |
| Emcure | 1975 | 2300 | 16% |
| Cholamandalam Investment | 1843 | 2160 | 17% |
Emcure PharmaceuticalsEmcure Pharmaceuticals continues to strengthen its domestic and international pharmaceutical franchise through broad-based growth across Europe, Canada and ROW markets, supported by improved execution, niche products and a strong commercial network. In Q1FY27, revenue grew 22.8% YoY to INR25.8bn, EBITDA increased 25.8% YoY to INR5.1bn and adjusted PAT rose 34% YoY to INR2.9bn.However, gross margin contracted 340bp YoY to 58.4%, while India business grew a relatively modest 10% YoY. Management expects low-to-mid teen revenue growth with 70-100bp EBITDA margin expansion in FY27, supported by continued international growth, new product launches and stronger domestic execution. We estimate 15%/21%/25% revenue/EBITDA/PAT CAGR over FY26-28.Cholamandalam Investment & Finance Company LtdCholamandalam Investment (CIFC) is shifting from a vehicle-finance specialist to a diversified lending platform, and this broadening mix is what underpins the next phase of compounding. Mortgage is becoming the key growth engine alongside the core vehicle-finance franchise, while gold loans, consumer finance and MSME add higher-yielding, more diversified earnings streams.Margins stay resilient even as funding costs tick up. NIM is expected at 7.3%/7.1% in FY27E/FY28E despite a likely 10-20bp rise in funding costs in 2HFY27, cushioned by a favorable funding mix and rising contribution from higher-yielding businesses.With credit costs normalizing and operating leverage improving, RoA should climb from 2.3% (FY26) to 2.7% (FY27E/FY28E), with RoE holding around 20%. We forecast ~21%/~27% AUM/PAT CAGR over FY26-28E. At ~4.1x FY27E P/BV, CIFC trades above vehicle-financing peers, but we see this as justified by superior growth, improving returns and broader diversification. (Disclaimer: Recommendations and views on the stock market, or any other asset classes or personal finance management tips given by experts and analysts are their own. These opinions do not represent the views of The Times of India.)
